Serum levels of the cancer-testis antigen POTEE and its clinical significance in non-small-cell lung cancer.
BACKGROUND:POTEE (POTE ankyrin domain family, member E) is a newly identified cancer-testis antigen that has been found to be expressed in a wide variety of human cancers including cancers of the colon, prostate, lung, breast, ovary, and pancreas. AIM:To measure the serum levels of POTEE in patients...
Main Authors: | , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2015-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4393100?pdf=render |
id |
doaj-74897c0bf9d74661bedece92b445e242 |
---|---|
record_format |
Article |
spelling |
doaj-74897c0bf9d74661bedece92b445e2422020-11-25T02:33:33ZengPublic Library of Science (PLoS)PLoS ONE1932-62032015-01-01104e012279210.1371/journal.pone.0122792Serum levels of the cancer-testis antigen POTEE and its clinical significance in non-small-cell lung cancer.Qi WangXuefei LiShengxiang RenNingning ChengMingchuan ZhaoYishi ZhangJiayu LiWeijing CaiChao ZhaoWa CaoCaicun ZhouBACKGROUND:POTEE (POTE ankyrin domain family, member E) is a newly identified cancer-testis antigen that has been found to be expressed in a wide variety of human cancers including cancers of the colon, prostate, lung, breast, ovary, and pancreas. AIM:To measure the serum levels of POTEE in patients with non-small-cell lung cancer (NSCLC) and to explore the clinical significance of POTEE in NSCLC. PATIENTS AND METHODS:104 NSCLC patients, 66 benign lung disease patients and 80 healthy volunteers were enrolled in this study from May 2013 to February 2014. Serum POTEE levels were measured using enzyme-linked immunosorbent assay (ELISA). Numerical variables were recorded as means ± standard deviation (SD) and analyzed by independent t tests. Categorical variables were calculated as rates and were analyzed using a χ2 test or Fisher's exact test. Survival curves were estimated and compared using the Kaplan-Meier method and log-rank tests. RESULTS:Serum POTEE levels were significantly higher in NSCLC patients than in benign lung disease patients and healthy controls (mean ± SD [pg/ml], 324.38± 13.84 vs. 156.93 ± 17.38 and 139.09 ± 15.80, P<0.001) and were significantly correlated with TNM stage. Survival analysis revealed that patients with low serum POTEE had longer progression-free survival (PFS) than those with high serum POTEE (P=0.021). Cox multivariate analysis indicated that POTEE was an independent prognostic factor of progression-free survival (P =0.009, hazard ratio, 2.440). CONCLUSIONS:Serum POTEE level in NSCLC patients is associated with TNM stage and is a potential prognostic factor.http://europepmc.org/articles/PMC4393100?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Qi Wang Xuefei Li Shengxiang Ren Ningning Cheng Mingchuan Zhao Yishi Zhang Jiayu Li Weijing Cai Chao Zhao Wa Cao Caicun Zhou |
spellingShingle |
Qi Wang Xuefei Li Shengxiang Ren Ningning Cheng Mingchuan Zhao Yishi Zhang Jiayu Li Weijing Cai Chao Zhao Wa Cao Caicun Zhou Serum levels of the cancer-testis antigen POTEE and its clinical significance in non-small-cell lung cancer. PLoS ONE |
author_facet |
Qi Wang Xuefei Li Shengxiang Ren Ningning Cheng Mingchuan Zhao Yishi Zhang Jiayu Li Weijing Cai Chao Zhao Wa Cao Caicun Zhou |
author_sort |
Qi Wang |
title |
Serum levels of the cancer-testis antigen POTEE and its clinical significance in non-small-cell lung cancer. |
title_short |
Serum levels of the cancer-testis antigen POTEE and its clinical significance in non-small-cell lung cancer. |
title_full |
Serum levels of the cancer-testis antigen POTEE and its clinical significance in non-small-cell lung cancer. |
title_fullStr |
Serum levels of the cancer-testis antigen POTEE and its clinical significance in non-small-cell lung cancer. |
title_full_unstemmed |
Serum levels of the cancer-testis antigen POTEE and its clinical significance in non-small-cell lung cancer. |
title_sort |
serum levels of the cancer-testis antigen potee and its clinical significance in non-small-cell lung cancer. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2015-01-01 |
description |
BACKGROUND:POTEE (POTE ankyrin domain family, member E) is a newly identified cancer-testis antigen that has been found to be expressed in a wide variety of human cancers including cancers of the colon, prostate, lung, breast, ovary, and pancreas. AIM:To measure the serum levels of POTEE in patients with non-small-cell lung cancer (NSCLC) and to explore the clinical significance of POTEE in NSCLC. PATIENTS AND METHODS:104 NSCLC patients, 66 benign lung disease patients and 80 healthy volunteers were enrolled in this study from May 2013 to February 2014. Serum POTEE levels were measured using enzyme-linked immunosorbent assay (ELISA). Numerical variables were recorded as means ± standard deviation (SD) and analyzed by independent t tests. Categorical variables were calculated as rates and were analyzed using a χ2 test or Fisher's exact test. Survival curves were estimated and compared using the Kaplan-Meier method and log-rank tests. RESULTS:Serum POTEE levels were significantly higher in NSCLC patients than in benign lung disease patients and healthy controls (mean ± SD [pg/ml], 324.38± 13.84 vs. 156.93 ± 17.38 and 139.09 ± 15.80, P<0.001) and were significantly correlated with TNM stage. Survival analysis revealed that patients with low serum POTEE had longer progression-free survival (PFS) than those with high serum POTEE (P=0.021). Cox multivariate analysis indicated that POTEE was an independent prognostic factor of progression-free survival (P =0.009, hazard ratio, 2.440). CONCLUSIONS:Serum POTEE level in NSCLC patients is associated with TNM stage and is a potential prognostic factor. |
url |
http://europepmc.org/articles/PMC4393100?pdf=render |
work_keys_str_mv |
AT qiwang serumlevelsofthecancertestisantigenpoteeanditsclinicalsignificanceinnonsmallcelllungcancer AT xuefeili serumlevelsofthecancertestisantigenpoteeanditsclinicalsignificanceinnonsmallcelllungcancer AT shengxiangren serumlevelsofthecancertestisantigenpoteeanditsclinicalsignificanceinnonsmallcelllungcancer AT ningningcheng serumlevelsofthecancertestisantigenpoteeanditsclinicalsignificanceinnonsmallcelllungcancer AT mingchuanzhao serumlevelsofthecancertestisantigenpoteeanditsclinicalsignificanceinnonsmallcelllungcancer AT yishizhang serumlevelsofthecancertestisantigenpoteeanditsclinicalsignificanceinnonsmallcelllungcancer AT jiayuli serumlevelsofthecancertestisantigenpoteeanditsclinicalsignificanceinnonsmallcelllungcancer AT weijingcai serumlevelsofthecancertestisantigenpoteeanditsclinicalsignificanceinnonsmallcelllungcancer AT chaozhao serumlevelsofthecancertestisantigenpoteeanditsclinicalsignificanceinnonsmallcelllungcancer AT wacao serumlevelsofthecancertestisantigenpoteeanditsclinicalsignificanceinnonsmallcelllungcancer AT caicunzhou serumlevelsofthecancertestisantigenpoteeanditsclinicalsignificanceinnonsmallcelllungcancer |
_version_ |
1724813186104819712 |